KLRK1 and neoplasm: KLRK1 (or NKG2D) is also an activating receptor expressed by NK cells and T cell subsets, can augment the cytotoxicity of NK cells/T cells or synergize with immune checkpoint inhibitors to eliminate tumor cells [30].